vs
Side-by-side financial comparison of Prime Medicine, Inc. (PRME) and Personalis, Inc. (PSNL). Click either name above to swap in a different company.
Personalis, Inc. is the larger business by last-quarter revenue ($17.3M vs $838.0K, roughly 20.7× Prime Medicine, Inc.). Personalis, Inc. runs the higher net margin — -137.3% vs -5498.7%, a 5361.4% gap on every dollar of revenue. On growth, Personalis, Inc. posted the faster year-over-year revenue change (3.2% vs -61.6%). Personalis, Inc. produced more free cash flow last quarter ($-22.3M vs $-37.5M).
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Personalis, Inc. is a precision medicine company specializing in advanced oncology genomics solutions. It develops proprietary genomic sequencing and data analytics platforms to support biopharmaceutical partners in immunotherapy development and clinical providers in delivering personalized cancer care, with operations spanning North America, Europe and key Asia-Pacific markets.
PRME vs PSNL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $838.0K | $17.3M |
| Net Profit | $-46.1M | $-23.8M |
| Gross Margin | — | 11.0% |
| Operating Margin | -5800.5% | -145.7% |
| Net Margin | -5498.7% | -137.3% |
| Revenue YoY | -61.6% | 3.2% |
| Net Profit YoY | -9.0% | -45.0% |
| EPS (diluted) | $-0.22 | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $838.0K | $17.3M | ||
| Q3 25 | $1.2M | $14.5M | ||
| Q2 25 | $1.1M | $17.2M | ||
| Q1 25 | $1.5M | $20.6M | ||
| Q4 24 | $2.2M | $16.8M | ||
| Q3 24 | — | $25.7M | ||
| Q2 24 | $0 | $22.6M | ||
| Q1 24 | $591.0K | $19.5M |
| Q4 25 | $-46.1M | $-23.8M | ||
| Q3 25 | $-50.6M | $-21.7M | ||
| Q2 25 | $-52.6M | $-20.1M | ||
| Q1 25 | $-51.9M | $-15.8M | ||
| Q4 24 | $-42.3M | $-16.4M | ||
| Q3 24 | — | $-39.1M | ||
| Q2 24 | $-55.3M | $-12.8M | ||
| Q1 24 | $-45.8M | $-13.0M |
| Q4 25 | — | 11.0% | ||
| Q3 25 | — | 13.2% | ||
| Q2 25 | — | 27.6% | ||
| Q1 25 | — | 35.0% | ||
| Q4 24 | — | 27.1% | ||
| Q3 24 | — | 34.0% | ||
| Q2 24 | — | 35.6% | ||
| Q1 24 | — | 28.1% |
| Q4 25 | -5800.5% | -145.7% | ||
| Q3 25 | -4406.0% | -160.7% | ||
| Q2 25 | -4787.2% | -126.7% | ||
| Q1 25 | -3603.3% | -85.9% | ||
| Q4 24 | -2025.7% | -107.8% | ||
| Q3 24 | — | -55.9% | ||
| Q2 24 | — | -74.8% | ||
| Q1 24 | -8179.5% | -96.7% |
| Q4 25 | -5498.7% | -137.3% | ||
| Q3 25 | -4129.1% | -149.4% | ||
| Q2 25 | -4716.7% | -116.6% | ||
| Q1 25 | -3568.8% | -76.4% | ||
| Q4 24 | -1936.6% | -97.8% | ||
| Q3 24 | — | -152.0% | ||
| Q2 24 | — | -56.7% | ||
| Q1 24 | -7743.0% | -66.4% |
| Q4 25 | $-0.22 | $-0.26 | ||
| Q3 25 | $-0.32 | $-0.24 | ||
| Q2 25 | $-0.41 | $-0.23 | ||
| Q1 25 | $-0.40 | $-0.18 | ||
| Q4 24 | $-0.31 | $-0.23 | ||
| Q3 24 | — | $-0.64 | ||
| Q2 24 | $-0.46 | $-0.24 | ||
| Q1 24 | $-0.44 | $-0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.0M | $240.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $120.9M | $261.2M |
| Total Assets | $342.7M | $334.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.0M | $240.0M | ||
| Q3 25 | $71.4M | $150.5M | ||
| Q2 25 | $53.8M | $173.2M | ||
| Q1 25 | $91.9M | $185.7M | ||
| Q4 24 | $182.5M | $185.0M | ||
| Q3 24 | — | $143.7M | ||
| Q2 24 | $55.6M | $87.0M | ||
| Q1 24 | $94.2M | $95.4M |
| Q4 25 | $120.9M | $261.2M | ||
| Q3 25 | $161.8M | $171.4M | ||
| Q2 25 | $60.9M | $190.8M | ||
| Q1 25 | $106.9M | $207.3M | ||
| Q4 24 | $153.1M | $203.0M | ||
| Q3 24 | — | $166.8M | ||
| Q2 24 | $196.6M | $112.3M | ||
| Q1 24 | $243.8M | $120.7M |
| Q4 25 | $342.7M | $334.2M | ||
| Q3 25 | $385.0M | $242.8M | ||
| Q2 25 | $279.0M | $258.7M | ||
| Q1 25 | $328.2M | $273.3M | ||
| Q4 24 | $297.5M | $270.3M | ||
| Q3 24 | — | $239.9M | ||
| Q2 24 | $259.7M | $185.5M | ||
| Q1 24 | $311.4M | $195.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.3M | $-22.2M |
| Free Cash FlowOCF − Capex | $-37.5M | $-22.3M |
| FCF MarginFCF / Revenue | -4480.4% | -128.7% |
| Capex IntensityCapex / Revenue | 34.6% | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-167.1M | $-79.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-37.3M | $-22.2M | ||
| Q3 25 | $-35.0M | $-21.8M | ||
| Q2 25 | $-41.4M | $-12.9M | ||
| Q1 25 | $-48.9M | $-18.0M | ||
| Q4 24 | $16.2M | $-7.8M | ||
| Q3 24 | — | $-6.2M | ||
| Q2 24 | $-45.5M | $-10.7M | ||
| Q1 24 | $-67.7M | $-20.4M |
| Q4 25 | $-37.5M | $-22.3M | ||
| Q3 25 | $-35.3M | $-23.4M | ||
| Q2 25 | $-43.0M | $-13.2M | ||
| Q1 25 | $-51.3M | $-20.5M | ||
| Q4 24 | $14.5M | $-9.0M | ||
| Q3 24 | — | $-6.4M | ||
| Q2 24 | $-47.4M | $-10.7M | ||
| Q1 24 | $-70.0M | $-20.5M |
| Q4 25 | -4480.4% | -128.7% | ||
| Q3 25 | -2880.5% | -161.6% | ||
| Q2 25 | -3855.1% | -76.9% | ||
| Q1 25 | -3526.8% | -99.4% | ||
| Q4 24 | 662.1% | -53.8% | ||
| Q3 24 | — | -25.1% | ||
| Q2 24 | — | -47.6% | ||
| Q1 24 | -11849.6% | -105.1% |
| Q4 25 | 34.6% | 0.4% | ||
| Q3 25 | 20.2% | 11.2% | ||
| Q2 25 | 141.0% | 1.7% | ||
| Q1 25 | 166.6% | 12.2% | ||
| Q4 24 | 82.0% | 7.4% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | 393.2% | 0.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRME
Segment breakdown not available.
PSNL
| Population Sequencing | $11.8M | 68% |
| Related Party | $5.4M | 31% |
